Koltan names Frank Karbe to board
This article was originally published in Scrip
New Haven, Connecticut-based Koltan Pharmaceuticals has named Frank Karbe, former chief financial officer of Exelixis, to its board of directors. Mr Karbe has more than two decades of international experience in finance and business development. Previously, Mr Karbe held various positions in the finance department of The Royal Dutch/Shell Group in Europe. And since January 2010, he has been a member of the board and chair of the audit committee for Tekmira Pharmaceuticals, a publicly held biopharmaceutical company.
You may also be interested in...
In the latest instalment of our VC playbook series, In Vivo sits down with Roel Bulthuis, managing partner at INKEF Capital, to discuss the group’s approach to health care investing in Europe, the importance of funding a team not just a project and how life sciences venture capital is evolving with the emergence of health tech.
Our readers have been voting and the results have been counted. The winners of In Vivo's annual Deals Of The Year contest are ...
It is time for In Vivo's 12th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.